News

Light-it Group Launches Enlighten Ventures: A Micro-VC Initiative to Propel Healthtech Innovation

Javier Lempert (CTO & Founder), Alan Brande (CEO & Founder) and Martin Oppenheimer (COO & Founder) at Light-it’s HQ. AVENTURA,…

1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in…

1 year ago

Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ORANGE, Calif. , Dec. 20, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present…

1 year ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical…

1 year ago

Commure Acquires Memora Health, a Digital Care Navigation Platform, to Enhance Intelligent Care Navigation

MOUNTAIN VIEW, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Commure, a leading healthcare technology company, announced today the acquisition of…

1 year ago

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric…

1 year ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in…

1 year ago

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira…

1 year ago

Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading…

1 year ago

NervGen Announces “At-The-Market” Equity Program

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a…

1 year ago